Stocks to Watch 09-10-07

TARRAGON CORP (NASD: TARR)
"Up 182.3% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/TARR.php

Tarragon Corporation is a leading developer of multifamily housing for rent and for sale. Tarragon's operations are concentrated in the Northeast, Florida, Texas and Tennessee. To learn more about Tarragon Corporation, visit: www.tarragoncorp.com.

TARR News:

September 7 - Tarragon Corporation Closes $69.25 Million Property Sale and Reaches Understanding With Largest Creditor for Reinstatement of Over $550 Million of Loans

Tarragon Corporation (NASDAQ: TARR) recently announced that it has closed the sales of two of its Florida rental properties for $69.25 million and that it has reached agreement with its largest creditor, General Electric Capital Corporation (GECC), on the terms, which Tarragon expects to be satisfied early next week, under which GECC will reinstate all loans that it has made to Tarragon and/or its affiliates.

The proceeds from the sale of the two Florida properties have allowed Tarragon to satisfy approximately $50 million of outstanding indebtedness, bring current all debt service that had been owed to GECC and to establish certain cash and other reserves. Further, in addition to the property sales announced recently, Tarragon also has accepted offers or entered into contracts to sell additional properties in Florida and Tennessee over the next 30 days. Such sales, if completed, would generate approximately $35 million in net proceeds while reducing Tarragon's outstanding debt by about $270 million.

The Florida property sales, agreement with GECC and the above-referenced property sales are part of an overall Tarragon plan designed to restore liquidity and improve its financial condition. As part of this plan, Tarragon is in discussions with other significant lenders. As described above, the plan currently contemplates additional property sales, the proceeds of which would be used to repay or bring current Tarragon's obligations under other loan agreements and to provide Tarragon with additional liquidity.

There can be no assurance, however, that the contemplated property sales will be completed on acceptable terms or in a timely manner, that Tarragon will complete its agreement with GECC or that it will be able to reach agreements with other lenders. If not, it may be necessary for Tarragon to undertake such other actions as may be appropriate in the light of its current liquidity situation.

UNIFY CORP (OTCBB: UFYC)
"Up 42% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/UFYC.php

Unify is a global provider of application modernization software that enables Service-Oriented Architecture (SOA). Unify allows an organization to modernize mission critical applications while maximizing its legacy investments throughout the enterprise. Unify's enterprise software portfolio enhances SOA environments by improving application time-to-market metrics, increasing collaboration and service-enabling legacy information. Headquartered in Sacramento, Calif., Unify has offices in London, Munich, Paris and Sidney. Visit www.unify.com or email us at This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

UFYC News:

September 6 - Unify Reports Strong Fiscal 2008 First Quarter Results

"We are pleased to achieve operating income, positive cash flow and triple digit revenue growth during the first quarter, which is seasonally our weakest quarter," commented Todd Wille, CEO of Unify. "Our software licenses and services revenues grew significantly year-over-year. Our recurring maintenance revenues, which represented 60% of total Q1 revenues, remained strong with renewals in excess of 95 percent. For the second quarter in a row, we were operating cash flow positive. Additionally, we added 79 new customers in our database and development software business as we continue to see the combination of Unify and GUPTA creating new opportunities around the world."

Mr. Wille continued, "With the application modernization side of our business, we have become an endorsed partner of Microsoft with our Composer for Lotus Notes offering. We are engaged with the Microsoft sales teams in addition to working with large solution integrators to engage with customers that want to modernize their Lotus Notes applications. We completed 10 proof of concept migration projects. Our Composer for Lotus Notes solution provides enterprises the only viable alternative to an expensive rewrite for transitioning their Lotus Notes applications to either the Microsoft or Java platforms. We believe this is a tremendous opportunity for Unify as large organizations with hundreds to thousands of applications written in Lotus Notes look for ways to move these mission critical applications and data to new SOA enabled platforms. In the second quarter, we expect to expand our relationship with Microsoft to market our Composer Solution.

"We are in an exciting period of growth and we look forward to further expanding the reach of our compelling product and services offerings. During the second quarter, we will be conducting customer conferences in Sweden, Germany, France, North America, and Russia for our software business. Additionally, during the second quarter we will be introducing major new product releases of our development and database products, which will bring additional visibility, momentum and results to an already stellar beginning of the fiscal year," concluded Mr. Wille.

HOLLIS-EDEN PHARMACEUTICALS (NASD: HEPH)
"Up 40.8% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/HEPH.php

Hollis-Eden Pharmaceuticals, Inc. is a world leader in the development of a proprietary class of adrenal steroid hormones as novel pharmaceuticals for human health. Through its Hormonal Signaling Technology Platform, Hollis-Eden is developing a new series of small molecule compounds that are metabolites or synthetic analogs of endogenous hormones derived by the adrenal glands from the body's most abundant circulating steroid. These steroid hormones, designed to restore the biological activity of cellular signaling pathways disrupted by disease and aging, have been demonstrated in humans to possess several properties with potential therapeutic benefit -- they regulate innate and adaptive immunity, reduce nonproductive inflammation and stimulate cell proliferation. The Company's clinical drug development candidates include HE3286, a next-generation compound currently in a clinical trial for the treatment of type 2 diabetes and being prepared for potential clinical trials in rheumatoid arthritis, and HE3235, a next-generation compound selected for cancer. In addition to these clinical development candidates, Hollis-Eden has an active research program that is generating additional new clinical leads that are being further evaluated in preclinical models of a number of different diseases. For more information on Hollis-Eden, visit the Company's website at www.holliseden.com.

HEPH News:

September 7 - Hollis-Eden Pharmaceuticals Presents HE3235 Update at ASCO Breast Cancer Symposium

Hollis-Eden Pharmaceuticals, Inc. (NASDAQ: HEPH), the leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, recently reported on its progress with HE3235, its investigational oral drug candidate for the treatment of cancer. Data being presented recently at The 2007 ASCO Breast Cancer Symposium, being held September 7-8 in San Francisco, California, demonstrate that HE3235, as previously reported, significantly inhibited the incidence of new tumors and stopped the growth of existing tumors in a preclinical model of breast cancer. Updated data presented at this conference indicate that existing tumors in the HE3235-treated animals from this preclinical model had still not progressed and no new tumors were reported during the five weeks of observation after dosing stopped, in contrast to the vehicle-treated animals in which tumors continued to proliferate. Additionally, the Company reported that when animals with existing tumors were dosed at one half the strength of the lowest dose previously tested, HE3235 stopped tumor progression in these animals.

The new data indicating that the anti-tumor benefit of HE3235 was sustained for five weeks after dosing stopped are striking in light of the fact that approved breast cancer treatments lose activity once treatment is discontinued. The Company plans to file an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) in the first quarter of 2008 in order to initiate a planned Phase I/II clinical trial with HE3235 for the treatment of cancer.

The previously reported data being presented at the Breast Cancer Symposium are from an animal model in which rats were given the potent carcinogen N-methyl-N-nitrosourea to induce multiple breast tumors. Animals with detected tumors were randomized to receive one of two strengths of HE3235 or assigned to a placebo control group. Treatment with HE3235 resulted in a reduced tumor burden for existing tumors that were present before treatment commenced compared to placebo-treated animals (p less than 0.001). In addition, after the treatment period began, all placebo control treated animals developed one or more additional tumors, while not a single new tumor arose in the animals treated with HE3235. This preventive action of HE3235 on the occurrence of new tumors also reached statistical significance (p less than 0.01).

"The effect of HE3235 to inhibit new tumor growth and stop tumor progression in this model was impressive, but what was unexpected and exciting was that the compound appeared to have a lasting effect even after dosing was stopped," stated Dr. Rajkumar Lakshmanaswamy, Assistant Professor, Department of Pathology, Texas Tech University Health Sciences Center, who conducted the study and reported on the findings at the ASCO symposium.

"These data hold the promise that HE3235, if successfully developed, could offer a new treatment option for women with breast cancer," stated Richard B. Hollis, Chairman and Chief Executive Officer of Hollis-Eden. "The lasting anti-tumor effect of HE3235 reported in this animal model of breast cancer suggests the compound is causing tumor cells to undergo apoptosis, or die. Therefore, the compound may act through a novel mechanism of action that could make it useful in treating multiple types of cancer. Due to this potential and the previously reported activity with HE3235 in prostate cancer models, we are aggressively pursuing the mechanism of action and the activity of the drug candidate in other models of cancer. HE3235 represents yet another novel pharmaceutical drug candidate developed out of our hormone signaling technology platform and yields a program in cancer to augment our expanding drug development pipeline in metabolic disorders and diseases of inflammation, such as type 2 diabetes and rheumatoid arthritis."

CHINA TECHNOLOGY DEVELOPMENT (NASD: CTDC)
"Up 29.4% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/CTDC.php

CTDC is engaged in information network security in the People's Republic of China. CTDC's ultimate principal shareholder is China Merchants Group (www.cmhk.com ), one of the most important Chinese state-owned enterprises in China. For more information, please visit our website at www.chinactdc.com .

CTDC News:

September 7 - China Technology Announces Entry to the Solar Energy Sector

China Technology Development Group Corporation (Nasdaq: CTDC) recently announced the new business strategy of entering the booming solar energy sector. With strong government commitment to significantly increase China's use of renewable energy in the coming decades and rising energy demand, CTDC strongly believes the new business strategy will deliver shareholder value and higher earnings potential for the Company.

The new business strategy has received the board's approval and strong endorsement from China Merchants Group ('China Merchants'), which is currently the Company's largest shareholder and one of the major Chinese state-owned conglomerate enterprises as well as one of the Big Four Chinese enterprises in Hong Kong. The Company will be holding the Annual General Meeting in October, 2007 to obtain the shareholders' approval.

In order to implement this new strategy, the Company has established a strategic partnership with a leading solar energy solution provider. The Company will introduce the technology developed by Terra Solar Global Inc., which is a U.S. company pioneering in thin film Photovoltaics (the 'Thin Film PV') industry. The Company will manufacture and sell the proprietary SnO2 base plate, a key component of a-Si (Amorphous Si) Thin Film PV products, which can optimize the performance of Building Integrated Photovoltaics (BIPV). Most importantly, the Company has become the first and only Chinese company based in China to apply this new generation technology, which is currently one of the leading technologies in the Thin Film PV industry.

ENERGY EXPLORATION (OTCBB: ENXTF)
"Up 17.5% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/ENXTF.php

NXT is in the business of providing wide-area airborne exploration services to the oil and gas industry. The Company utilizes its proprietary SFD Survey System to offer its clients a unique, low cost service to rapidly identify sub-surface structures with reservoir potential in sedimentary basins with no environmental impact. The value of the service is providing clients with an efficient, cost effective method of surveying large areas and delivering an inventory of SFD prospects with high potential. The SFD-based exploration process substantially reduces the need for 2-D reconnaissance seismic thus saving clients valuable time and money.

ENXTF News:

September 6 - NXT Reports Second Quarter Financial and Operational Results

Energy Exploration Technologies Inc. (OTCBB: ENXTF)(FRANKFURT: EFW), is pleased to announce its financial and operating results for the six months ended June 30, 2007. The unaudited consolidated financial statements and management discussion and analysis were filed August 29, 2007 on SEDAR at www.sedar.com. These reports are also available on EDGAR at www.sec.gov/edgar.shtml or on the Company's website at www.nxtenergy.com.

We are pleased to report our financial results for the six month period ended June 30, 2007. The completion of Stress Field Detection ("SFD") contracts in the second quarter of 2007 resulted in the recognition of US $2,480,000 (Cdn $2,764,000) of SFD survey revenue. We are also pleased to report net income of US $749,000 for the first half of the year and three consecutive quarters of positive cash flow generated from operating activities. We believe these financial results signify a turning point in the Company's history. We now have a core team, the right business plan and a growing customer base, which is expected to lead to continued profitability. We are grateful to the many shareholders who have supported the Company throughout the years to make this accomplishment possible. We intend to build on this success and look to the future with confidence.

Following the implementation of the 2006 business plan, we have completed SFD surveys for four independent clients. These clients are now actively pursuing the SFD prospects identified in these surveys. Most notably, Pengrowth Corporation has accumulated a significant land position on the trend in the Puskwa area of Alberta based upon the SFD recommendations. Follow up seismic has confirmed the SFD prospects. Third party wells drilled along the trend have established a prolific regional oil play.

We are pleased that Pengrowth has incorporated the SFD survey system in a significant exploration program. Management of Pengrowth has given presentations in various investor forums which mentioned the potential value of the SFD to rapidly identify oil and natural gas prospects at low cost and risk. This support coupled with the endorsement of other clients is creating a growing interest in utilizing our services within the oil and gas community.

On August 27, 2007 we announced Cdn. $9.0 million of new contracts, creating an order book of surveys to be completed through the balance of the third and fourth quarters of 2007 and into 2008. We are confident that we will add to our order book from both existing and new clients.

To meet growing operational demands, in the last eighteen months we have achieved significant advancements in our overall capabilities. Accomplishments include the development of enhanced data collection hardware and software, the introduction of a new generation of sensors and an increase in the number of operational SFD sensors. Additionally, we have increased interpretation capacity through the hiring of several key members to our technical staff and the ongoing identification of SFD signal templates. During the remainder of 2007 we plan to complete the implementation of a new interpretation theatre and to acquire an aircraft managed and operated by a third party.

We believe that the business plan that we embarked upon in early 2006 is working. We have repositioned ourselves successfully as an oil and gas service provider with a revenue model based upon survey and interpretation fees and royalties. We have now achieved positive earnings, increased our operational capacity and achieved visible success that is gaining industry acceptance. We are confident that we are well positioned for continued growth in the future.

SEQUIAM CORP (OTCBB: SQUM)
"Up 13.7% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/SQUM.php

Headquartered in Orlando, Florida, Sequiam Corporation develops, markets, and supports a portfolio of highly robust proprietary biometrically enabled consumer lifestyle and commercial products and OEM solutions. In addition, Sequiam has invested heavily in research and development to develop unique products and solutions for the biometric industry worldwide. Sequiam's biometric solutions incorporate low-cost, high-volume manufacturing processes targeted at the consumer and commercial market. Sequiam is a global company with offices in Taiwan, China, and South Africa. For more information, please visit http://www.sequiam.com.

SQUM News:

September 7 - Sequiam Biometrics Successfully Passes California Department of Justice Firearm Safety Device Test(s) for the BioVault 2.0

Sequiam Biometrics, a subsidiary of Sequiam Corporation (OTCBB: SQUM), a leading provider of innovative consumer lifestyle biometric technologies and services, announced that it has successfully passed United States Test Laboratory (USTL) test(s) as required by California Penal Code Sections 12088 and Regulation Section 977.45, Chapter 12.6, Division 1, Title 11, of the California Code of Regulations.

Amongst the performed tests were: picking the BioVault, forced removal, tensile test, shock test, sawing test and drop test.

Sequiam's Chief Executive Officer, Nick VandenBrekel, said: "We are pleased with the results of this rigorous test as performed by the USTL and it shows once again that Sequiam is dedicated to providing products of the highest quality and integrity. The BioVault 2.0 has been a very popular product since its introduction to the marketplace and we are soon to introduce a smaller version called the BioBox which we shall submit to the same high standards of testing."